Skin Conditions & Dermatology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

This Phase 3 trial is testing amlitelimab, a new injectable medicine, for people 12 years and older who have moderate-to-severe atopic dermatitis, a common form of eczema. Patients who do not respond well to creams and ointments may find amlitelimab offers a new way to manage their symptoms. The study is large, lasting up to 24 weeks with over 600 participants across several countries.

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

This Phase 3 study is exploring if Patidegib Gel 2%, a topical treatment, can help adults with Gorlin syndrome prevent new basal cell skin cancers on the face. Gorlin syndrome is a rare genetic condition that increases the risk of developing these cancers. If this gel works, it could reduce the number of surgeries and treatments needed by these patients over time. The trial will run for a year and includes 140 adults worldwide.

Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne

This Phase 2 trial is looking at the safety of a new mRNA vaccine designed to reduce acne in teenagers aged 12 to 17. Acne can be tough to treat and can affect self-esteem, so a vaccine with fewer side effects than current treatments could be very helpful. The study includes up to 410 participants and lasts about 13 months to carefully monitor effects.

Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis

This study investigates whether keeping the natural, protective coating called vernix on a newborn's skin right after birth can help prevent atopic dermatitis in babies. This simple and natural approach might reduce eczema risk during the first year of life, improving skin health from the start. More than 1,300 mother and baby pairs in Chile are part of this study.

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

This Phase 2 trial is testing TolaSure, a topical gel, for children and adults with epidermolysis bullosa simplex, a rare condition where the skin blisters easily. If TolaSure reduces blistering, it could offer a new, gentle treatment option to improve daily comfort and skin health. The study is recruiting in the United States and involves daily application over several months.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.